蛋白浓缩管Pierce™ 蛋白浓缩管 PES,3K MWCO,2-6 mL
蛋白浓缩管Pierce™ 蛋白浓缩管 PES,5K MWCO,20-100 mL
蛋白浓缩管 Pierce™ 蛋白浓缩管 PES,10K MWCO,0.5 mL
蛋白浓缩管 Pierce™ 蛋白浓缩管 (PES),50K MWCO,2–6 mL
蛋白A包被板Pierce™ Protein A Coated Plates, White, 96-Well
蛋白名称:ACE2人重组蛋白,10108-H02H
蛋白构建:A DNA sequence encoding the extracellular domain (Met 1-Ser 740) of human ACE2 precursor (NP_068576.1) was expressed with the fused Fc region of human IgG1 at the C-terminus.
表达宿主:HEK293 Cells
蛋白纯度:≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.
蛋白活性:
1.Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2 (2019-nCoV) Spike S1-His (Cat: 40591-V08B1) at 2 μg/mL (100 μL/well) can bind human ACE2 (hFc tag) (Cat: 10108-H02H), the * of ACE2 is 5-35 ng/mL.
2.Captured ACE2(10108-H02H on proA Chip can bind SARS-CoV-2 B.1.1.529 (Omicron) Spike S1 Protein (Cat.No.40591-V08H41) with an affinity constant of 11.78 nM as determined in a SPR assay (Biacore T200)(Routinely tested).
3.Captured ACE2(10108-H02H on anti-Human IgG Fc via CM5 Chip can bind SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (Cat. No. 40592-V08H121) with an affinity constant of 5.667 nM as determined in a SPR assay (Biacore T200)(Routinely tested).
4.Loaded SARS-CoV-2 (2019-nCoV) Spike RBD-mFc Recombinant Protein (Cat. No. 40592-V05H) on AMC Biosensor, can bind Recombinant Human ACE2 Protein , hFc Tag (Cat. No. 10108-H02H) with an affinity constant of 7.34 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested).
蛋白内毒素:< 1.0 EU per μg of the protein as determined by the LAL method
预测N端:Gln 18
蛋白分子量:The recombinant human ACE2/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 961 amino acids and predicts a molecular mass of 110.3 kDa. As a result of glycosylation, the rhACE2/Fc monomer migrates as approximately 145-150 kDa band in SDS-PAGE under reducing conditions.
蛋白NP号:NP_068576.1
蛋白氨基酸序列:Met1-Ser740
蛋白标签:C-human IgG1-Fc
欢迎去义翘神州网查看ACE2人重组蛋白,10108-H02H详细信息。网址:https://cn.sinobiological.com/recombinant-proteins/human-ace2-10108-h02h
义翘神州研发团队拥有多年的重组蛋白研发经验。多年来,我们的团队已开发出超过9300余种重组蛋白,涵盖免疫检查点、抗体药物靶点、CAR-T细胞治疗靶点、Fc受体、流感病毒蛋白以及细胞因子等热门研究领域。义翘神州重组蛋白具有高纯度、高生物活性和低内毒素水平等特性,可为生物药靶点发现、蛋白质结构和功能分析、细胞疗法和重组酶酶学性质等科学研究提供支持。
欢迎小伙伴来咨询哦! 请注明来源、姓名,单位!
关注义翘神州或添加微信“sinobio2023"进行联系!
报价:面议
已咨询22次蛋白
报价:面议
已咨询27次蛋白
报价:面议
已咨询22次蛋白
报价:面议
已咨询24次蛋白
报价:面议
已咨询34次蛋白
报价:面议
已咨询26次蛋白
报价:面议
已咨询23次蛋白
报价:面议
已咨询26次蛋白
报价:面议
已咨询17次蛋白
报价:面议
已咨询30次其他重组蛋白
报价:面议
已咨询32次其他重组蛋白
报价:面议
已咨询43次其他重组蛋白
报价:面议
已咨询38次其他重组蛋白
报价:面议
已咨询36次其他重组蛋白
报价:面议
已咨询16次其他重组蛋白